Other

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advenchen Laboratories Nanjing Ltd

Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group

Xunqiang Wang

Xiquan Zhang

Min Zhou

Yang Zhang

Jie Xu

Ling Yang

Shanchun Wang

Xin Tian

Hai Jiang

Wei Shi

Xiangjian Wang

Xi Han

Hongjiang Xu

Jie Chen

Ping Dong

Jie Dai

Xiaole Zhan

Yadong Miu

Hao Yu

Hongmei Gu

Ping Xu

Wenjun Geng

Peng Lv

Zhongnan Xu

Chaoqiang Yang

Mengxue Fan

Fan Feng

Nan Su

Chi Zhang

Yao Liu

Zhengdong Cai

Yuchen Fan

Jun Shen

Shaonan Tang

Shuqing Cao

Maoqiong Pan

Yingqi Hua

Chengqian Wang

Lifan Tu

Yadong Miao

Hongsheng Wang

Pu Li

Mengxiong Sun

Zhuoying Wang

Zhaoqiang Yang

Gangyang Wang

The present application relates to the field of biomedicine, and relates to a combined pharmaceutical composition for treating biliary tract tumor, liver cancer, triple negative breast cancer or lung cancer. The combined pharmaceutical composition comprises an anti-PD-L1 antibody and anlotinib, and has good anti-biliary tract tumor, liver cancer, triple negative breast cancer or lung cancer activity.

Combined pharmaceutical composition for treating tumor

The present invention provides a quinoline derivative for treating triple-negative breast cancer and use thereof in preparing a pharmaceutical composition for treating a tumor. Specifically, the present invention relates to use of quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine in the treatment of triple-negative breast cancer, 

Quinoline derivative for treatment of triple-negative breast cancer

The present invention provides a quinoline derivative for the treatment of nasopharyngeal carcinoma and use thereof in preparation of a pharmaceutical composition for tumor treatment.

Quinoline derivative for treatment of nasopharyngeal carcinoma

The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclo propylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of lung adenocarcinoma, and relative to placebo, can significantly improve lung adenocarcinoma patients without progression of survival.

Quinoline derivatives for non-small cell lung cancer

Provided in the present invention is a quinoline derivative for treating gastric cancer. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt, a hydrate or a prodrug thereof as provided in the present application can effectively treat gastric cancer, and can stabilize or relieve the state of illness of a gastric cancer patient.

Quinoline derivative for treating gastric cancer

Provided in the present invention are a use of quinoline derivatives for treating oesophageal cancer and a treatment method, a pharmaceutical composition and a kit thereof. The 1-[[[4-(4-fluoro-2-methyl-1H-indole-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine provided by the present invention can effectively treat oesophageal cancer, and reduce the sum of the diameters of patient's target lesions.

Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof

The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of lung adenocarcinoma, and relative to placebo, can significantly improve lung adenocarcinoma patients without progression of survival.

Quinoline derivative against non-small cell lung cancer

The present invention provides 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopro-pylamine used for combating a tumor. Specially, the present invention refers to method for treating tumor, pharmaceutical composition and medicinal kit related to the described compound. Administrating the compound with a suitable dosage regimen can not only make the patient's plasma concentration maintain the level of 100 ng/ml or lower, but also achieve effects of treatments and obtain benefits for various tumours.

Method for treating tumour, pharmaceutical composition and medicinal kit

The present invention addresses methods and uses of quinoline derivatives in the treatment of tumors and pharmaceutical compositions for treatment of same. Specifically, the present invention involves a method and applications for the use of the quinoline derivative 1-[[[4-(4-fluoro-2-methyl-H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same.

Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same

The present invention addresses methods and uses of quinoline derivatives in the treatment of tumors and pharmaceutical compositions for treatment of same. Specifically, the present invention involves a method and applications for the use of the quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same.

Growing community of inventors

Jiangsu, China

Xunqiang Wang